Infection in burns.
Settle
J A
JA
D000287:Administration, Topical; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000382:microbiology / Q000401:mortality / Q000517:prevention & control; D002053:Burn Units; D002056:Burns / Q000382:microbiology*; D002648:Child; D003091:Colistin / Q000627:therapeutic use; D004780:Environment, Controlled; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008712:Methicillin / Q000494:pharmacology; D010403:Penicillin Resistance; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000401:mortality; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification; D012837:Silver Sulfadiazine / Q000627:therapeutic use; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification; D006113:United Kingdom; D014946:Wound Infection / Q000188:drug therapy / Q000382:microbiology* / Q000401:mortality / Q000517:prevention & control
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D008712:Methicillin; D012837:Silver Sulfadiazine; D003091:Colistin